William J. Gradishar, MD, Director, Maggie Daley Center for Women's Cancer Care, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, describes results from the 301 Study that compared eribulin mesylate (Halaven) to capecitabine in patients with locally advanced or metastatic breast cancer following treatment with anthracyclines or taxanes.
For more on this study, visit [ Ссылка ]
